Klotho Neurosciences, Inc. (NASDAQ:KLTO) Short Interest Update

Klotho Neurosciences, Inc. (NASDAQ:KLTO) was the recipient of a large decline in short interest in the month of December. As of December 15th, there was short interest totaling 248,611 shares, a decline of 50.3% from the November 30th total of 500,273 shares. Based on an average daily trading volume, of 748,749 shares, the short-interest ratio is currently 0.3 days. Approximately 0.5% of the company’s stock are short sold. Approximately 0.5% of the company’s stock are short sold. Based on an average daily trading volume, of 748,749 shares, the short-interest ratio is currently 0.3 days.

Institutional Trading of Klotho Neurosciences

A hedge fund recently bought a new stake in Klotho Neurosciences stock. Jane Street Group LLC bought a new position in shares of Klotho Neurosciences, Inc. (NASDAQ:KLTO) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm bought 23,364 shares of the company’s stock, valued at approximately $26,000. Jane Street Group LLC owned about 0.05% of Klotho Neurosciences as of its most recent SEC filing. Institutional investors own 20.07% of the company’s stock.

Klotho Neurosciences Price Performance

Shares of NASDAQ:KLTO traded down $0.02 during midday trading on Monday, reaching $0.33. The company had a trading volume of 1,024,736 shares, compared to its average volume of 11,733,146. The stock has a market capitalization of $23.63 million, a P/E ratio of -1.02 and a beta of 10.05. The stock’s fifty day moving average price is $0.46 and its 200-day moving average price is $0.75. Klotho Neurosciences has a one year low of $0.11 and a one year high of $3.91.

Klotho Neurosciences (NASDAQ:KLTO) last released its earnings results on Thursday, November 13th. The company reported ($0.05) earnings per share for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Klotho Neurosciences in a research note on Monday, December 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Klotho Neurosciences presently has an average rating of “Sell”.

About Klotho Neurosciences

Klotho Neurosciences, Inc, a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases.